PTGS2 and melanoma: Consistently, previous studies have demonstrated that COX-2 expression is associated with PD-L1 expression and immune evasion in melanoma (37) and breast cancer (38), thereby providing a rationale for evaluating COX-2 inhibition to prevent tumor immune evasion (38).